APOE and Human
Cognosci Awarded Two Phase I SBIR Grants for Drug Development
RESEARCH TRIANGLE PARK, N.C., February 21, 2007 - Cognosci, Inc., an established pharmaceutical company with proprietary anti-inflammatory compounds based on apolipoprotein-E, announced that it was awarded two new Small Business Innovation Research grants worth over $525,000. The first grant, "Novel Therapy for Sepsis," was received from the National Institute of Allergy and Infectious Disease (NIAID) and the second, "Novel Intervention for Colitis," was from the National Institute of Diabetes And Digestive And Kidney Diseases (NIDDK).
"Cognosci is proud to be the recipient of these new grants to further our development programs," said Dr. Michael P. Vitek, Cognosci's Founder and President. "This brings Cognosci to a total of more than $8 million in awards from the prestigious SBIR program. We feel that our continued success in winning these national competitions for peer-reviewed awards continues to validate the therapeutic potential of our compounds for treating debilitating and life threatening diseases."
To date, Cognosci has collected over $7.5 million in SBIR funds with these newest awards adding another half-million and pending awards that may add another $2 million in the next year.
The receipt of these awards adds new collaborative investigators at Duke University and at Vanderbilt University to the extensive roster of academic collaborators for Cognosci. Dale Christensen, Cognosci's VP of Research and Business Development stated, "Our collaborators provide Cognosci with a great level of valuable expertise that allows us to evaluate the therapeutic and mechanistic properties of our compounds in a way that we could not pursue on our own. Each time a collaborator reports positive data, it provides external validation of the utility of Cognosci's compounds to treat disease."
About Cognosci, Inc.
Cognosci Inc. was founded in May 2000 to develop anti-inflammatory and neuro-restorative compounds for therapeutic treatment of neurodegnerative diseases such as Multiple Sclerosis, Alzheimer's Disease, and Traumatic Brain Injuries. Each of these disorders has a pharmacogenomic linkage to apolipoprotein-E gene and patients carrying the 4 allele of the APOE gene typically suffer worse outcomes. Cognosci scientists have created novel apoE-based compounds with potent anti-inflammatory and neuroprotective activities that are in preclinical development for the treatment of multiple sclerosis and other degenerative indications.
Source: Cognosci, Inc.
Contact: Dale Christensen, Ph.D.
VP of Business Development
Cognosci Receives Funding for Advanced Testing of Lead Drug Candidate for the Treatment of Multiple Sclerosis
For more information, contact:
2 Davis Drive
Research Triangle Park